Cytokinetics Inc. (CYTK) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Cytokinetics’s revenue went from $106M in fiscal 2016 to $88M in fiscal 2025, a decline of about 2.1% a year.
Net income in fiscal 2025 was -$785M, a net margin of -891.6%; the best year in this period was 2016 with $16M.
Over the twelve months to September 30, 2026, revenue was $113M and net income -$778M.
Free cash flow was -$535M in fiscal 2025 and positive in 1 of the 10 years shown.
The diluted share count rose 182% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $113M | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$708M | -$612M | -$536M | -$496M | -$324M | -$186M | -$94M | -$99M | -$89M | -$113M | $19M |
| Net income | -$778M | -$785M | -$590M | -$526M | -$389M | -$215M | -$127M | -$122M | -$106M | -$128M | $16M |
| EPS (diluted) | $-6.04 | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | $-2.11 | $-1.95 | $-2590.00 | $390.00 |
| R&D | $403M | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M |
| Revenue growth | — | +376.6% | +145.3% | −92.0% | +34.3% | +26.2% | +107.8% | −14.7% | +135.6% | −87.4% | +271.3% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$572M | -$510M | -$396M | -$414M | -$300M | -$143M | $9M | -$91M | -$101M | -$102M | $37M |
| Capital spending | -$17M | -$25M | -$4M | -$1M | -$11M | -$49M | -$11M | -$3M | -$889000 | -$3M | -$2M |
| Free cash flow | -$589M | -$535M | -$400M | -$416M | -$311M | -$191M | -$2M | -$94M | -$102M | -$105M | $35M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $131M | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $882M | $1.1B | $615M | $783M | $472M | $464M | $225M | $199M | $269M | $156M |
| Debt | — | $1.1B | $751M | $778M | $789M | $174M | $49M | $52M | $53M | $32M | $30M |
| Equity | — | -$660M | -$135M | -$386M | -$108M | $244M | $113M | -$11M | $26M | $110M | $94M |
| Total assets | — | $1.4B | $1.4B | $824M | $1.0B | $841M | $534M | $290M | $211M | $295M | $170M |
| Shares (diluted) | 129M | 0M | 0M | 0M | 0M | 0M | 0M | 0M | 0M | 0M | 0M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | -625.2% | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% |
| Net margin | -686.6% | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% |
| FCF margin | -519.5% | -607.5% | -2164.1% | -5521.2% | -328.6% | -271.8% | -3.8% | -348.1% | -324.1% | -782.7% | 33.3% |
| ROIC | — | -103.7% | -68.8% | -100.2% | -37.6% | -35.2% | -45.6% | -190.8% | -112.5% | -80.1% | 15.0% |
| ROE | — | 119.0% | 435.5% | 136.2% | 360.5% | -88.3% | -112.3% | 1112.7% | -409.8% | -116.3% | 17.4% |
Frequently asked questions
What is Cytokinetics’s annual revenue?
$88M in fiscal 2025 and $113M over the twelve months to September 30, 2026.
How much profit does Cytokinetics make?
Net income was -$785M in fiscal 2025 (net margin -891.6%).
Is Cytokinetics’s revenue growing?
Yes: revenue rose 376.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.